Study of the use of antidepressants for depression in dementia: The HTA-SADD trial- A multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine

Health Technology Assessment

Volumn 17, Issue 7, 2013, Pages 1-43

  Banerjee, S ^a   Hellier, J ^b   Romeo, R ^b   Dewey, M ^b   Knapp, M ^b   Ballard, C ^b   Baldwin, R ^c   Bentham, P ^d   Fox, C ^e   Holmes, C ^f   Katona, C ^g   Lawton, C ^h   Lindesay, J ⁱ   Livingston, G ^g   Mccrae, N ^b   Moniz Cook, E ^j   Murray, J ^b   Nurock, S ^k   Orrell, M ^g   O'Brien, J ^l   Poppe, M ^b   Thomas, A ^l   Walwyn, R ^b   Wilson, K ^m   Burns, A ^c   more..

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ UNIVERSITY OF LEICESTER   (United Kingdom)

^j UNIVERSITY OF HULL   (United Kingdom)

^k ALZHEIMER'S SOCIETY   (United Kingdom)

^l NEWCASTLE UNIVERSITY   (United Kingdom)

^m UNIVERSITY OF LIVERPOOL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MIRTAZAPINE; PLACEBO; SERTRALINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EAR NOSE THROAT DISEASE; ENDOCRINE DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEALTH CARE UTILIZATION; HEMATOLOGIC DISEASE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SEDATION; SIDE EFFECT; SKIN DISEASE; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COST-BENEFIT ANALYSIS; DEMENTIA; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIANSERIN; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; QUESTIONNAIRES; SERTRALINE; TREATMENT OUTCOME;

EID: 84875083835     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta17070     Document Type: Article

References (69)

1. Hofman A, Rocca WA, Brayne C, et al. The prevalence of dementia in Europe. Int J Epid 1991;20:736-48.
2. Launer LJ, Brayne C, Dartigues J-F, et al. Epilogue. Neuroepidemiology 1992;11:119-21.
3. Prince M, Jackson J. World Alzheimer's Report 2009. London: Alzheimer's Disease International; 2009.
4. Knapp M, Prince, M, Albanese E, Banerjee S, Dhanasiri S, et al. Dementia UK: the full report. London: Alzheimer's Society; 2007.
5. Lowin A, Knapp M, McCrone P. Alzheimer's disease in the UK: comparative evidence on cost of illness and volume of research funding. Int J Geriatr Psychiatry 2001;16:1143-8.
6. Wimo A, Prince M. World Alzheimer's Report 2010: the global economic impact of dementia. London, UK: Alzheimer's Disease International; 2010.
7. Department of Health (DoH). National service framework for older people. London: DoH; 2001.
8. Department of Health (DoH). Everybody's business. London: CSIP; 2005.
9. Department of Health (DoH). Everybody's business. London: CSIP; 2005. Living well with dementia, a national dementia strategy. London, UK: Stationery Office; 2008.
10. National Audit Office (NAO) Report. Improving services and support for people with dementia. HC 604, Report by the Comptroller and Auditor General, Session 2006-2007, TSO: London; 2007.
11. Murray J, Schneider J, Banerjee S, Mann A. EUROCARE: a cross-national study of co-resident spouse carers for people with Alzheimer's disease: II-A qualitative analysis of the experience of caregiving. Int J Geriatr Psych 1999;14:662-7.
12. Schneider J, Murray J, Banerjee S, Mann A. EUROCARE: a cross national study of co-resident spouse carers for people with Alzheimer's disease: I-Factors associated with carer burden. Int J Geriatr Psychiatry 1999;14:651-61.
13. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease III: Disorders of mood. Br J Psychiatry 1990;157:81-6.
14. Ballard CG, Bannister C, Oyebode F. Depression in Dementia Sufferers-A Review. Int J Geriatr Psychiatry 1996;11:507-15.
15. Burns A. Affective symptoms in Alzheimer's Disease Int J Geriatr Psychiatry 1991;6:371-6.
16. Greenwald BS, Kramer-Ginsberg E, Marin DB, Laitman LB, Hermann CK, Mohs RC, et al. Dementia with coexistent major depression. Am J Psychiatry 1989;146:1472-8.
17. Bains J, Birks JS, Dening TR. The efficacy of antidepressants in the treatment of depression in dementia. Cochrane Database Syst Rev 2002;4:CD003944.
18. Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc 2011;49:577-85.
19. Modrego PJ. Depression in Alzheimer's Disease. Pathophysiology, diagnosis, and treatment. J Alzheimers Dis 2010;21:1077-87.
20. Thompson S, Herrmann N, Rapoport MJ, Lanctôt KL. Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a meta-analysis. Can J Psychiatry 2007;52:248-55.
21. Petracca G, Teson A, Chemerinski E, Leiguarda R, Starkstein SE. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatr Clin Neurosci 1996;8:270-5.
22. Reifler BV, Teri L, Raskind M, Veith R, Barnes R, White E, et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry 1989;146:45-9.
23. Lyketsos C, Sheppard J, Steele C, Steele C, Brandt J, Steinberg M, et al. A randomized placebocontrolled, double-blind, clinical trial of sertraline in the treatment of depression complicating Alzheimer's Disease. Am J Psychiatry 2000;157:1686-9.
24. Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003;60:737-46.
25. Alexopoulos GS, Abrams RC, Young RC, Shamoian C. Cornell scale for depression in dementia. Biol Psychiatry 1988;23:271-84.
26. Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry 2010;18:136-45.
27. Weintraub D, Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry 2010;8:332-40.
28. Anonymous. Do SSRIs cause gastrointestinal bleeding? Drugs Ther Bull 2004;42:17-18.
29. Doody R, Stevens J, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: management of dementia (an evidence based review). Neurology 2000;56:1156-66.
30. Eccles M, Clarke J, Livingston M, Freemantle M, Mason J. North of England evidence based guidelines development project: guideline for the primary care management of dementia. BMJ 1998;317:802-8.
31. National Institute for Health and Clinical Excellence/Social Care Institute for Excellence (NICE/SCIE). Dementia: supporting people with dementia and their carers in health and social care. London: Department of Health; 2006.
32. Ensrud KE, Blackwell TL, Mangione CM, Bowman PJ, Whooley MA, Bauer DC, et al. Study of Osteoporotic Fractures Research Group. Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc 2002;50:1629-37.
33. Nyth A, Gottfries C, Luby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without dementia. Acta Psychiatry Scand 1991;86:138-45.
34. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 2002;52:1166-74.
35. Oslin D, Ten Have T, Streim J, Datto CJ, Weintraub D, DiFilippo S, et al. Probing the safety of medications in the frail elderly: evidence from a randomized controlled clinical trial of sertraline and venlafaxine in depressed nursing home residents. J Clin Psychiatry 2003;64:875-82.
36. Banerjee S. Services for older adults. In Thornicroft G, Smuzkler G, editors. Textbook of community psychiatry. London: Oxford University Press; 2001. pp. 81-396.
37. Ballard CG, Patel A, Solis M, Lowe K, Wilcock G. A one year follow up study of depression in dementia sufferers. Br J Psychiatry 1996;68:287-91.
38. Ballard CG, O'Brien JT, Swann AG, Thompson P, Neill D, McKeith IG. The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistence and new cases over 1 year of follow-up. J Clin Psychiatry 2001;62:46-9.
39. Ballard C, O'Brien J, Swann A, Fossey J, Lana M. A one year follow-up study of behavioural and psychological symptoms in dementia (BPSD) amongst people in care environments. J Clin Psychiatry 2001;62:631-6.
40. Teri L, Gibbons LE, McCurry SM, Logsdon RG, Buchner DM, Barlow WE, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA 2003;290:2015-22.
41. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM, et al. Clinical diagnosis of Alzheimer's Disease: report of the NINCDS-ADRDA work group. Neurology 1984;34:939-44.
42. Netten A. Costing informal care. In Netten A, Beecham J, editors. Costing community care: theory and practice. Ashgate: Aldershot; 1993.
43. Smith SC, Lamping DL, Banerjee S, Harwood R, Foley B, Smith, et al. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. Psychol Med 2006;37:737-46.
44. The EuroQoL Group. EuroQoL-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
45. Folstein MF, Folstein SE, McHugh PR. Mini Mental State. J Psychiatric Res 1975;12:189-98.
46. Goldberg D, Williams P. A user's guide to the General Health Questionnaire. Windsor: NFERNELSON; 1988.
47. Ware JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33.
48. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 1980;20:649-55.
49. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14.
50. Rosen WG, Terry RD, Fuld PA, et al. Pathologic verification of ischemic score in differentiation of Dementias. Ann Neurol 1980:7:486-8.
51. Beecham J, Knapp M. Costing Psychiatric Interventions. In G Thornicroft, editor. Measuring Health Needs. 2nd edn. London: Gaskell; 2001. pp. 200-24.
52. Curtis L. Unit costs of health and social care. Canterbury: PSSRU, University of Kent; 2010.
53. Department of Health (DoH). National Health Service schedule of reference costs 2010. URL: www.doh.gov.uk/nhsexec/refcosts.htm (accessed May 2010).
54. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 59, March 2010. London: BMA and RPS, 2007.
55. Curtis L. Unit costs of health and social care. Canterbury: PSSRU, University of Kent; 2007.
56. Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD. Provisional diagnostic criteria for depression of Alzheimer Disease. Am J Geriatr Psychiatry 2002;10:129-41.
57. Moniz-Cook E, Vernooij-Dassen M, Woods R, Verhey F, Chattat R, De Vugt M, et al. A European consensus on outcome measures for psychosocial intervention research in dementia care. Aging Ment Health 2008;12:14-29.
58. Schittecatte M, Dumont F, Machowski R, Cornil C, Lavergne F, Wilmotte J. Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology 2002;46:197-201.
59. Muehlbacher M, Nickel MK, Nickel C, Kettler C, Lahmann C, Pedrosa Gil F, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005;25:580-3.
60. Naglie G, Tomlinson G, Tansey C, Irvine J, Ritvo P, Black SE, et al. Utility-based Quality of Life measures in Alzheimer's disease. Qual Life Res 2006;15:631-43.
61. Banerjee S. Use of antipsychotics for people with dementia-time for action. London: Department of Health; 2009.
62. Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, Irvine C. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998;155:54-61.
63. Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev 2009;3:CD003945.
64. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, et al. Alzheimer's Disease Cooperative Study. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000;55:1271-8.
65. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry 1990;157:894-901.
66. Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, et al. CALM-AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007;357:1382-92.
67. Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 2005;20:459-64.
68. Cakir S, Kulaksizoglu IB. The efficacy of mirtazapine in agitated patients with Alzheimer's disease: a 12-week open-label pilot study. Neuropsychiatr Dis Treat 2008;4:963-6.
69. National Institute for Health and Clinical Excellence (NICE). Depression-the treatment and management of depression in adults. London: NICE; 2009.